11/18/2026 | Press release | Distributed by Public on 11/18/2026 03:53
Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak, has raised $400 million in a Series D funding round, valuing the company at $3.5 billion as it expands its work on vision restoration and technologies designed to interact directly with the human brain.
The company announced the funding in a blog post, while a person familiar with the transaction told TechCrunch that investors placed its valuation at $3.5 billion. The latest round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
Founded in 2021, Science was established to develop technologies that improve scientists' understanding of the brain and create new ways of interacting with it. Hodak, who previously co-founded Neuralink with Elon Musk and served as its president, has pursued neuroscience and biotechnology since his university years. He reportedly gained access to a graduate neuroscience laboratory while still an undergraduate, an early experience that helped shape his research interests.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Nigeria Capital Market Masterclass.
The company's immediate commercial focus is PRIMA, a system combining an implantable chip with wearable technology to help people with age-related macular degeneration regain some vision. The device has received approval in Europe and is available in Germany. Science is also investigating its potential use in other conditions that cause blindness.
Hodak announced at TechCrunch Disrupt that PRIMA is now being tested in patients with Stargardt's disease, an inherited condition that causes progressive vision loss. The trial extends the company's effort to establish whether the technology can address a wider range of retinal disorders.
A major priority for the new funding is securing access to the US market through the Food and Drug Administration's Humanitarian Device Exemption (HDE) pathway. The regulatory route allows certain medical devices intended to treat rare conditions to be used in the United States, subject to FDA approval.
Science has persuaded the FDA that advanced macular degeneration affecting both eyes is sufficiently uncommon to qualify for consideration under the humanitarian device framework. The company is seeking approval to make PRIMA available to eligible patients in the country.
The pathway could provide a route to US deployment without requiring the company to follow the standard approval process designed for devices targeting larger patient populations. However, eligibility under the humanitarian framework does not automatically grant market access. Science must still satisfy the FDA's requirements for the device and its proposed use.
PRIMA's progress is important to the company's near-term development because it gives Science a clinical programme with an existing European regulatory foothold while it pursues more experimental work. The Stargardt's disease trial could also help establish the technology's potential beyond age-related macular degeneration, although its effectiveness in each condition will need to be demonstrated through clinical testing.
Science's broader objective is more ambitious than restoring limited vision. The company is developing a bio-hybrid sensor that combines cultured neurons with silicon, with the aim of creating a direct interface between biological neural systems and electronic technology.
The approach differs from conventional brain-computer interfaces that rely primarily on electrodes to record or stimulate neural activity. By incorporating living neurons into the sensor, Science is exploring whether biological components can provide a different way to interact with the brain.
The company is designing initial human trials of the technology in collaboration with Murat Günel, a Yale neurosurgery professor. Günel told TechCrunch that the platform could eventually support potential treatments for Parkinson's disease, as well as other brain injuries and neurological illnesses.
Those applications remain prospective. The company has not yet established through human trials that its bio-hybrid technology can treat these conditions. Its current work is focused on preparing the initial studies needed to assess the system's safety and potential clinical value.
The distinction between Science's two programmes is quite notable. PRIMA is an implantable vision-restoration system that has already reached patients in Europe and is being evaluated for additional conditions. The bio-hybrid sensor remains at an earlier stage, with human trials still being designed.
The $400 million financing gives Science additional resources to pursue both tracks: expanding the clinical and regulatory development of its vision technology while advancing a more experimental effort to connect living neural tissue with computing systems.
The $3.5 billion valuation also places a substantial expectation on the company's ability to translate its research into medical applications.